Compounds for treating cancer

A compound of Formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• Ring A is a C3-C10 cycloalkyl optionally substituted with 1-3 independently selected R1;
• each R1 is independently selected from halogen and C1-C6 alkyl;
• Ring B is 5-10 membered heteroaryl optionally substituted with 1-3 independently selected R2;
• each R2 is independently selected from halogen, cyano, C1-C6 alkyl, and C1-C6 haloalkyl;
• Ring C is C4-C6 cycloalkyl, 4-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, wherein Ring C is optionally substituted with 1-3 independently selected R3;
• each R3 is independently selected from halogen, cyano, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, —NRARB, —SO2RA, —NHSO2RA, and —SO2NRARB,
• each RA and RB is independently selected from hydrogen, C1-C6 alkyl, and C1-C6 haloalkyl;
• or
• RA and RB together with the nitrogen atom to which they are attached form a 4-8 membered heterocyclyl optionally substituted with 1-2 substituents independently selected from halogen and C1-C6 alkyl;
• L1 is a bond;
• L2 is —NH— or —N(CH3)—;
• L3 is a bond, —NH—, —N(CH3)—, —O—, *—SO2NH—, *—NHSO2—, *—C(═O) NH—, or *—NHC(═O)—, wherein * denotes the point of connection to Ring C;
• X is a C2-C15 alkylene, a C4-C15 alkenylene, or a C5-C15 alkynylene, wherein X is optionally substituted with 1-6 independently selected RY and wherein 1-4 methylene units of X are optionally and independently replaced by —O—, —NH—, —N(C1-C6 alkyl)-, —(C3-C6 cycloalkyl)-, or -(5-6 membered heteroaryl)-;
• each Rx is independently selected from halogen and C1-C6 alkyl;
• L4 is a bond, *—(CH2)m—O—C(═O) NH—, or *—(CH2)m—NHC(═O) NH—, wherein * indicates the point of attachment to Ring A;
• and
• m is 0, 1, or 2.